The STROLL study represents the latest commitment by Cordis to continue its groundbreaking work in the fight against vascular disease.Dr. Gray is compensated for his services as a member of the company’s scientific advisory board and provides other consulting services.
Cordis Corporation Announces One-Year Results From The STROLL Trial
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts